Patents Examined by Jegatheesan Seharaseyon
  • Targeted and mutated human-interferon fusion proteins
    Patent number: 10946070
    Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER, UNIVERSITAT OSNABRUCK
    Inventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
  • Human anti-IFN-? antibodies
    Patent number: 10941198
    Abstract: Provided are novel IFB-a binding molecules of human origin, particularly human-derived anti-IFN-? antibodies as well as IFN-? binding fragments, derivatives and variants thereof. In addition, pharmaceutical compositions, kits, and methods for use in diagnosis and therapy are described.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 9, 2021
    Inventors: Syeda F. Y. Haque, Adrian Hayday, Kai Kisand, Kai Krohn, Annalisa Macagno, Steffen Meyer, Paert Peterson, Mike Rothe, Philip Vlaicu, Martin Woodward
  • Aortopathy
    Patent number: 10933119
    Abstract: The invention relates to aortopathy, and in particular, to compositions and methods for the diagnosis and treatment of aortopathy.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: March 2, 2021
    Assignee: University of Leicester
    Inventor: Toru Suzuki
  • Compositions for the treatment of rheumatoid arthritis and methods of using same
    Patent number: 10927435
    Abstract: The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R) with a DMARD.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: February 23, 2021
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Xiaohong Huang, Martine Jasson, Vanessa Marks, Allen Radin
  • Method to modulate pigmentation process in the melanocytes of skin
    Patent number: 10925929
    Abstract: The invention describes a method to modulate melanosome maturation process in melanocytes. Further, it describes a method to reversibly alter the process of pigmentation in the human epidermal skin. The method targets melanosome maturation and its transfer to keratinocytes, which are key processes involved in the pigmentation for its potential use in predictable and controlled regulation of pigmentation in human skin.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: February 23, 2021
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Rajesh Sudhir Gokhale, Vivek Tirunelveli Natarajan, Parul Ganju
  • IFN-gamma-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof
    Patent number: 10919976
    Abstract: Provided are IFN-?-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibodies and antigen-binding fragment thereof that bind to an activation-inducible TNFR (AITR) polypeptide. Various in vitro and in vivo methods and compositions related to IRTCA antibodies described herein are also provided. Methods include, for example, changing cytokine secretion from T cells in vivo or in vitro and prevention and/or therapeutic treatment of cancer using an IRTCA antibody or fragment thereof.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: February 16, 2021
    Assignee: Eutilex Co., Ltd.
    Inventors: Byoung S Kwon, Seoung-Joo Lee, Joong Won Lee, Seunghyun Lee
  • Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment
    Patent number: 10919950
    Abstract: The present application relates to fusion proteins, chimeric antigen bearing cells expressing fusion proteins and compositions comprising chimeric antigen bearing cells expressing fusion proteins. The application further relates to methods of using the fusion proteins, cells and compositions for modulating an immune response.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: February 16, 2021
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, Adam Johnson
  • Lyophilized pharmaceutical composition of Fc-peptide fusion protein
    Patent number: 10918698
    Abstract: A novel and thermostable lyophilized pharmaceutical composition of Romiplostim (Fcpeptide fusion protein) along with buffer, bulking agent, stabilizer, and surfactant at pH range of 4.0-6.0.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: February 16, 2021
    Assignee: INTAS PHARMACEUTICALS LTD.
    Inventors: Himanshu Gadgil, Chandresh Chhatbar, Vijaykant Pandey
  • Treatment for rheumatoid arthritis
    Patent number: 10913792
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 9, 2021
    Assignee: Morphosys AG
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
  • Targeted engineered interferon and uses thereof
    Patent number: 10906985
    Abstract: The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: February 2, 2021
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Lennart Zabeau, Jan Tavernier
  • Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
    Patent number: 10877024
    Abstract: The invention provides novel methods of determining or comparing potency of a test interferon relative to rSIFN-co (an interferon having therapeutic effects on solid tumors); methods of establishing substantial equivalence between a test interferon and rSIFN-co; as well as methods for determining potency of a test interferon, kits for determination of such methods, and an interferon or an interferon substitute having said activities.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: December 29, 2020
    Assignee: SUPERLAB FAR EAST LIMITED
    Inventor: Guangwen Wei
  • Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
    Patent number: 10874716
    Abstract: The invention provides a method and/or composition for the treatment of bone cancer including primary bone cancer and secondary bone cancer, breast cancer, skin cancer, nasopharyngeal carcinoma, oral cancer, vulva cancer, prostate cancer, cervical cancer, melanoma including melanocarcinoma by percutaneous and/or transmucosal administration of the interferon. Further, the invention provides a method and/or composition for the treatment of skin, subcutaneous, mucosal and/or submucosal primary cancer and cancer metastatic lesions by percutaneous and/or transmucosal administration of the interferon, especially a method and/or composition for the treatment of bone cancer pain including pain resulted by secondary bone cancer.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: December 29, 2020
    Assignee: SUPERLAB FAR EAST LIMITED
    Inventor: Guangwen Wei
  • Immunoglobulins and uses thereof
    Patent number: 10858413
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 8, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Ellen Chi
  • Biomarker signatures and uses thereof
    Patent number: 10859572
    Abstract: The invention provides a method for determining a Systemic Lupus Erythematosus-associated disease state in a subject comprising the steps of (a) providing a sample to be tested; and (b) measuring the presence and/or amount in the test sample of one or more biomarker(s) selected from the group defined in Table 1, wherein the presence and/or amount in the test sample of the one or more biomarker(s) selected from the group defined in Table 1 is indicative of a Systemic Lupus. The invention also provides an array and a kit suitable for use in the methods of the invention.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: December 8, 2020
    Assignee: Immunovia AB
    Inventors: Carl Arne Krister Borrebaeck, Lars Bertil Christer Wingren
  • Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof
    Patent number: 10851177
    Abstract: The present disclosure relates to a method for inhibiting intracellular activated (GTP-bound) RAS using an intact immunoglobulin-type antibody having the ability to penetrate the cytosol, and to the use thereof. The disclosure further relates to a heavy-chain variable region (VH) which induces an intact immunoglobulin-type antibody to penetrate the cytosol and bind to activated RAS in the cytosol, and to an antibody comprising the same. The disclosure correspondingly provides a method for inhibiting the growth of cancer or tumor cells using the antibody, and a method for treating cancer or tumor.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: December 1, 2020
    Assignee: ORUM THERAPEUTICS INC.
    Inventors: Yong-Sung Kim, Dong-Ki Choi, Seung-Min Shin, Sung-Hoon Kim
  • Method for the purification of G-CSF
    Patent number: 10844103
    Abstract: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 24, 2020
    Assignee: Mylan Pharmaceuticals Inc.
    Inventors: Arndt Dietrich, Bernhard Janowski, Jörg Schäffner, Ulrich Kurt Blaschke
  • Interferon beta antibodies and uses thereof
    Patent number: 10829553
    Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN?). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 10, 2020
    Assignees: PFIZER INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Stefano V. Gulla, Christine Huard, Janet Elizabeth Buhlmann, Juan Carlos Almagro, Sreekumar R. Kodangattil, Steven A. Greenberg, Edward Roland Lavallie, Eric M. Bennett, Lidia Mosyak, James Perry Hall, Anthony John Coyle
  • Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 10822421
    Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: November 3, 2020
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Kris Reedquist
  • Anti-CSPG4 fusions with interferon for the treatment of malignancy
    Patent number: 10822427
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha or to an interferon beta (IFN-?) or to a nutant interferon beta, or to an interferon gamma (IFN-?) or to a mutant interferon gamma.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: November 3, 2020
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, John M. Timmerman, Kham M. Trinh
  • Human interferon-beta variant conjugated immunocytokine and method for preparing same
    Patent number: 10806799
    Abstract: The present invention relates to an immunocytokine in which a human interferon-beta variant is conjugated to an antibody or a fragment thereof, and a method for preparing the same. The human interferon-beta variant has superior activity or functions compared with natural interferon-beta, and the productivity of the immunocytokine according to the present invention is excellent. In addition, the immunocytokine according to the present invention can be favorably used as a target therapeutic agent for multiple sclerosis or cancer since the immunocytokine express both of functions of the interferon-beta and characteristics of the antibody binding to a specific antigen.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: October 20, 2020
    Assignee: GENOPHARM INC.
    Inventors: Young Kee Shin, Young Deug Kim, Jun Young Choi, Tae Eun Kim, Young Jin Lee, Ju Ho Lee, Yeong Mun Kim